NANO Nanobiotix SA

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Date: Tuesday, May 20, 2025

Time: 5:00 pm EDT / 11:00 pm CEST

Location: New York, NY

Presenters: Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link:

The fireside chats will be webcast live from the of the Investors section of the Company’s website. The replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at or follow us on and

Contacts

Nanobiotix 


Communications Department

Brandon Owens

VP, Communications

+1 (617) 852-4835

Investor Relations Department

Ricky Bhajun

Director, Investor Relations

+33 (0)6 42 05 34 15

 
Media Relations 


France – HARDY

Caroline Hardy

50





Global – uncapped

Becky Lauer

+1 (646) 286-0057

 

Attachments



EN
12/05/2025

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Free Trial
NANO NANOBIOTIX SA

Nanobiotix: 1 director

A director at Nanobiotix bought 10,000 shares at 2.900EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

18h / 2m 18h / 2m 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’...

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 mai 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202547 426 85149 535 88349 513 765 À prop...

May 14, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Voting Rights and Shares Capital of the Company

Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 14, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2April 30, 202547,426,85149,535,88349,513,765 About NANOBI...

May 14, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect...

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm...

May 12, 2025 1 EN
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C...

Nanobiotix participera à la 3ème conférence investisseurs annuelle H.C. Wainwright BioConnect au NASDAQ PARIS and CAMBRIDGE, Mass., 12 mai 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : 3ème conférence investisseurs ann...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch